Skip to main content
Clinical Trials/NCT01628016
NCT01628016
Completed
Not Applicable

A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy of Attentional Bias Modification Training in the Treatment of Depressive Symptoms

Hunan Normal University1 site in 1 country77 target enrollmentSeptember 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depressive Symptoms
Sponsor
Hunan Normal University
Enrollment
77
Locations
1
Primary Endpoint
Depressive Symptoms Measured by Beck Depression Inventory-II
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to test whether attention bias modification training is an effective neurobehavioral therapy to improve depressive symptoms.That is whether attention bias modification training is superior to placebo in reducing depressive symptoms over 1 year after training.

Detailed Description

Attentional bias has been theorized to play a critical role in the onset and maintenance of depression. Attentional bias modification training (ABMT), an experimental paradigm that uses training to induce adaptive attentional bias, was developed to test the causal model and this has therapeutic implications in depression.To test the effect of ABMT on treatment of depressive symptoms, a randomized, double-blind, placebo and blank controlled trial is conducted in college students who are experiencing mild-to-severe symptoms of depression.

Registry
clinicaltrials.gov
Start Date
September 2011
End Date
July 2013
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hunan Normal University
Responsible Party
Principal Investigator
Principal Investigator

Wenhui Yang

Department of Psychology

Hunan Normal University

Eligibility Criteria

Inclusion Criteria

  • A score of 14 or higher on the Beck Depression Inventory-II
  • Exclusion criteria :
  • a current episode of MDD, bipolar disorder, schizophrenia or organic mental disorder;
  • any concurrent psychotherapy;
  • any concurrent psychotropic medication.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Depressive Symptoms Measured by Beck Depression Inventory-II

Time Frame: From the baseline to posttraining, 2-, 4-, 8-week, 3-, 7-month follow-ups after training

Beck Depression Inventory-II(BDI-II) contains 21 items and rates the depressive symptoms for the past two weeks. Each question provides for a response of 0 to 3. A zero response means the depressive symptom is not present; a 1 means the symptom is present, a 2 means the symptom is moderate, and a 3 means the symptom is severe. The total BDI-II score is the sum of the individual items; total BDI-II scores can range from 0 to 63. Cutoff points developed by Beck, Steer, \& Brown (1997) for the total BDI-II are: 0 to 13, nondepressed; 14 to 19, mild depression; 20 to 28, moderate depression; 29 or more, severe depression.

Secondary Outcomes

  • Anxiety and Rumination Symptoms Measured by State-Trait Anxiety Inventory-Trait(STAI-T) and Rumination Response Style(RRS)(From baseline to post-training, 2-, 4-, 8-week, 3- , 7-month follow-ups after training)

Study Sites (1)

Loading locations...

Similar Trials